T1	outcome 1262 1286	grade 3 to 4 neutropenia
T2	outcome 1297 1332	grade 2 to 4 fatigue and neuropathy
T3	outcome 1135 1138	TTP
T4	iv-cont-median 1151 1155	6.14
T5	cv-cont-median 1158 1169	3.98 months
T7	iv-bin-percent 1214 1219	41.4%
T8	cv-bin-percent 1222 1227	26.2%
T9	outcome 960 975	Median survival
T10	iv-cont-median 986 997	18.6 months
T11	cv-cont-median 1005 1016	15.8 months
T14	intervention-participants 895 898	266
T15	control-participants 941 944	263
T16	intervention 0 27	Gemcitabine plus Paclitaxel
T17	control 35 45	Paclitaxel
T18	eligibility 61 133	patients with metastatic breast cancer and prior anthracycline treatment
T19	outcome-Measure 675 696	overall survival (OS)
T6	outcome 1199 1201	RR
T12	outcome-Measure 727 752	time to progression (TTP)
T13	outcome-Measure 754 772	response rate (RR)
T20	outcome-Measure 774 799	progression-free survival
T21	outcome-Measure 801 818	response duration
T22	outcome-Measure 824 832	toxicity
